Daxas Advisory Committee Review May Look At Inclusion Criteria For Pivotal Trials
This article was originally published in The Pink Sheet Daily
Executive Summary
Forest's oral COPD drug will go before FDA's Pulmonary-Allergy Drugs Advisory Committee on April 7.